ATE536886T1 - Stabilisierte feste zusammensetzungen von modifizierter faktor vii - Google Patents

Stabilisierte feste zusammensetzungen von modifizierter faktor vii

Info

Publication number
ATE536886T1
ATE536886T1 AT03720286T AT03720286T ATE536886T1 AT E536886 T1 ATE536886 T1 AT E536886T1 AT 03720286 T AT03720286 T AT 03720286T AT 03720286 T AT03720286 T AT 03720286T AT E536886 T1 ATE536886 T1 AT E536886T1
Authority
AT
Austria
Prior art keywords
factor vii
modified factor
solid compositions
stabilized solid
composition
Prior art date
Application number
AT03720286T
Other languages
English (en)
Inventor
Hanne Nedergaard
Lars Hansen
Niels Klausen
Troels Kornfelt
James Flink
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE536886T1 publication Critical patent/ATE536886T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Ceramic Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03720286T 2002-05-03 2003-05-02 Stabilisierte feste zusammensetzungen von modifizierter faktor vii ATE536886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200677 2002-05-03
PCT/DK2003/000287 WO2003092731A1 (en) 2002-05-03 2003-05-02 Stabilised solid compositions of modified factor vii

Publications (1)

Publication Number Publication Date
ATE536886T1 true ATE536886T1 (de) 2011-12-15

Family

ID=29286050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720286T ATE536886T1 (de) 2002-05-03 2003-05-02 Stabilisierte feste zusammensetzungen von modifizierter faktor vii

Country Status (6)

Country Link
EP (1) EP1503798B8 (de)
JP (1) JP5184738B2 (de)
AT (1) ATE536886T1 (de)
AU (1) AU2003223925A1 (de)
ES (1) ES2377959T3 (de)
WO (1) WO2003092731A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894071B2 (en) 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
BRPI0311959B8 (pt) † 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
EP3103869A1 (de) * 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Verfahren zur herstellung von factor vii polypeptiden
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
AU2011203354B2 (en) * 2003-12-19 2014-07-17 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
DE602004005564T2 (de) * 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
EP1921453A4 (de) * 2005-07-20 2008-12-31 Kyowa Medex Co Ltd Verfahren zur stabilisierung von in einer biologischen probe enthaltenem peptid
AU2007213476B2 (en) * 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
EP3287140B1 (de) 2015-04-21 2021-06-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nervenwachstumsfaktorzusammensetzung und pulverinjektion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
DE69233398D1 (de) * 1991-02-28 2004-09-16 Novo Nordisk As Modifizierter faktor-vii
WO2001082943A2 (en) * 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake

Also Published As

Publication number Publication date
WO2003092731A1 (en) 2003-11-13
EP1503798B1 (de) 2011-12-14
AU2003223925A1 (en) 2003-11-17
EP1503798B8 (de) 2012-03-14
JP2005530752A (ja) 2005-10-13
EP1503798A1 (de) 2005-02-09
ES2377959T3 (es) 2012-04-03
JP5184738B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
ATE536886T1 (de) Stabilisierte feste zusammensetzungen von modifizierter faktor vii
DE60232017D1 (de) Flüssige zusammensetzung aus faktor vii polypeptiden
CO4970765A1 (es) Composiciones de bajo ph que contienen acido para el cuidado personal que exhiben picazon reducida
CA2411373A1 (en) Stable liquid enzyme compositions with enhanced activity
DE60217844D1 (de) Trocknungszusammensetzung
NO952120D0 (no) Stabiliserte flytende enzymatiske blandinger
GB0101403D0 (en) Improvements in or relating to organic compositions
DE60115922D1 (de) Verfahren zur verzögerung der abbaugeschwindigkeit von bioabbaubarem polymer und bioabbaubare polymerzusammensetzungen
DE60000616D1 (de) Mineralwasser enthaltende Zusammensetzungen
ATE547114T1 (de) Flüssige zusammensetzungen von factor vii polypeptiden
ATE491749T1 (de) Inhibierung/verringerung der verfärbung von diorganopolysiloxanzusammensetzungen
EE9900022A (et) Värvuskompositsioon, mis koosneb pürogalloolstruktuure sisaldavast agendist, raud(II)soolast ning orgaanilisest happest
TR200401573T4 (tr) Stabilize edilmiş granülosit koloni uyarıcı faktör
DE69917245D1 (de) Betablocker enthaltende ophtalmische zusammensetzungen
TR200201392T2 (tr) Su ıslah maddesi
GB2387101A (en) Compositions containing creatine and creatinine
BR0214590A (pt) composições lìquidas de leveduras
BR0312177A (pt) Composição condicionadora dos cabelos, método de tratamento dos cabelos e uso de uma argila hidrofobicamente modificada
NO20022411D0 (no) Tilsatsmiddel til gjödsel
ATE322165T1 (de) Verwendung von pflanzlichem material zur bekämpfung von landschnecken
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
ATE205386T1 (de) Einphasige,transparente wässrige zusammensetzung
DK0651614T3 (da) Stabiliseret fødevaresammensætning
ATE294790T1 (de) Chlormethylierung von thiophene
ATE474603T1 (de) Stabilisiertes leukotrien b4 (ltb4) pharmazeutikum